Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of November 2022. The report serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data as of October 31, 2022.
- Issued Share Capital: 4,311,312,908 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 243,924,760 Ordinary Shares.
- Total Voting Rights: 4,067,388,148.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital as of October 31, 2022, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification regarding capital structure rather than a financial performance report.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (4,067,388,148) to determine notification thresholds under FCA rules.
- Verify the number of shares held in Treasury (243,924,760) when calculating outstanding shares.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.